Swiss National Bank Has $2.27 Million Holdings in DICE Therapeutics, Inc. (NASDAQ:DICE)

Swiss National Bank lifted its stake in shares of DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) by 223.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 72,800 shares of the company’s stock after buying an additional 50,300 shares during the period. Swiss National Bank owned about 0.15% of DICE Therapeutics worth $2,271,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of DICE. VR Adviser LLC bought a new stake in shares of DICE Therapeutics in the third quarter worth $15,514,000. Barclays PLC grew its stake in shares of DICE Therapeutics by 318.0% in the third quarter. Barclays PLC now owns 5,956 shares of the company’s stock worth $120,000 after purchasing an additional 4,531 shares during the last quarter. Credit Suisse AG bought a new stake in shares of DICE Therapeutics in the second quarter worth $138,000. Legal & General Group Plc grew its stake in shares of DICE Therapeutics by 265.1% in the second quarter. Legal & General Group Plc now owns 4,764 shares of the company’s stock worth $74,000 after purchasing an additional 3,459 shares during the last quarter. Finally, Arizona State Retirement System bought a new stake in shares of DICE Therapeutics in the fourth quarter worth $266,000. 91.51% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DICE Therapeutics

In related news, Director James Paul Scopa sold 10,000 shares of the firm’s stock in a transaction dated Friday, March 17th. The shares were sold at an average price of $29.05, for a total value of $290,500.00. Following the transaction, the director now owns 23,719 shares of the company’s stock, valued at approximately $689,036.95. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other DICE Therapeutics news, Director James Paul Scopa sold 10,000 shares of DICE Therapeutics stock in a transaction that occurred on Friday, March 17th. The shares were sold at an average price of $29.05, for a total transaction of $290,500.00. Following the transaction, the director now owns 23,719 shares of the company’s stock, valued at approximately $689,036.95. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kevin Judice sold 13,698 shares of DICE Therapeutics stock in a transaction that occurred on Wednesday, May 3rd. The stock was sold at an average price of $36.50, for a total transaction of $499,977.00. Following the transaction, the chief executive officer now directly owns 799,685 shares in the company, valued at approximately $29,188,502.50. The disclosure for this sale can be found here. In the last quarter, insiders have acquired 372,590 shares of company stock valued at $10,239,252 and have sold 154,210 shares valued at $5,611,071. 4.90% of the stock is owned by insiders.

DICE Therapeutics Stock Performance

Shares of NASDAQ DICE opened at $33.15 on Friday. DICE Therapeutics, Inc. has a fifty-two week low of $12.64 and a fifty-two week high of $45.99. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -15.21 and a beta of 0.69. The firm’s 50-day simple moving average is $31.34 and its 200 day simple moving average is $31.26.

DICE Therapeutics (NASDAQ:DICE – Get Rating) last announced its quarterly earnings results on Wednesday, March 15th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.02). On average, sell-side analysts predict that DICE Therapeutics, Inc. will post -2.57 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on DICE shares. Wells Fargo & Company started coverage on shares of DICE Therapeutics in a research report on Wednesday. They set an “equal weight” rating and a $38.00 price target on the stock. Needham & Company LLC started coverage on shares of DICE Therapeutics in a research report on Friday, March 31st. They set a “buy” rating and a $56.00 price target on the stock. Cowen started coverage on shares of DICE Therapeutics in a research report on Wednesday, March 1st. They set an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of DICE Therapeutics in a research report on Thursday, March 16th. Finally, TD Cowen began coverage on shares of DICE Therapeutics in a research report on Wednesday, March 1st. They set an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, DICE Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $62.60.

DICE Therapeutics Company Profile

(Get Rating)

DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.